Compliance certificate under Reg 74(5) of SEBI (DP) Regulations
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Ltd has submitted a routine quarterly compliance certificate for the quarter ended September 30, 2025, confirming that all share certificates received for dematerialization were properly mutilated, cancelled, and the depository was recorded as the registered owner within SEBI-prescribed timelines. The certificate, signed by Managing Director Umang Gosalia (DIN: 05153830) and confirmed by the company's Registrar Purva Sharegistry (India) Pvt. Ltd., covers dematerialization of about 5,100 shares from two shareholders — Riteshkumar Rameshbhai Dhol (3,000 shares on 07/07/2025) and Rajesh Dhirajlal Gantra (2,100 shares on 02/08/2025). This is a standard regulatory filing with no change in capital or ownership structure.
This is a routine procedural filing and has no direct impact on the stock price or shareholder value. It simply confirms compliance with SEBI's dematerialization rules for the quarter.